共研产业研究院通过对公开信息分析、业内资深人士和相关企业高管的深度访谈，以及分析师专业性判断 和评价撰写了《2025-2031年中国中药材银杏叶行业深度调查与前景趋势报告》。本报告为中药材银杏叶企 业决策人及投资者提供了重要参考依据。 为确保中药材银杏叶行业数据精准性以及内容的可参考价值，共研产业研究院团队通过上市公司年报、厂 家调研、经销商座谈、专家验证等多渠道开展数据采集工作，并运用共研自主建立的产业分析模型，结合 市场、行业和厂商进行深度剖析，能够反映当前市场现状、热点、动态及未来趋势，使从业者能够从多种 维度、多个侧面综合了解当前中药材银杏叶行业的发展态势。 银杏叶中黄酮类化合物对改善微循环、抑制血小板聚集的作用已被临床研究证实。随着心脑血管疾病发病 率上升，银杏叶制剂成为临床常用药物，直接拉动原料需求。预计2027年我国中药材银杏叶行业产值约 5948亿元。 2021-2027年中国中药材银杏叶行业产值预测及增速 中国60岁以上人口占比达21.1%，老年群体对心脑血管保健、记忆力改善等需求旺盛。银杏叶保健品（如 胶囊、口服液）因天然、低副作用特性，成为中老年人群首选，推动市场渗透率提升。预计2027 ...

向西，一列列国际班列驰骋亚欧大陆；向东，万吨货轮通达全球四海……作为"一带一路"交汇点，江苏 省正以全方位的开放之姿，连接中国与世界。 一连串亮眼的数据，成为江苏省开放活力的最佳注脚：外贸进出口跃上5万亿元台阶，进出口规模连续 22年居全国第二位，实际使用外资规模连续7年保持全国第一；全省有进出口实绩的企业8.76万家，占 全国的13.9%；外资规模始终保持全国首位，2024年实际使用外资190.5亿美元，四年累计1037.4亿美 元，占全国比重达16.2%。尤为值得一提的是，南京、苏州两座城市，已连续三轮成为服务贸易创新发 展试点地区，正崛起为数字文化、中医药、知识产权等特色服务出口的新高地。 习近平总书记在江苏考察时，赋予其新的重大使命——"建设具有世界聚合力的双向开放枢纽"。为何是 江苏？这片土地究竟有何独特之处？ 为探寻答案，9月15日起，《金融时报》记者跟随"活力中国调研行"江苏主题采访团，兵分"沿江线""沿 海线"两路，深入无锡、常州、扬州、南京、苏州、盐城、连云港六地，走进企业、港口、跨境电商产 业园区等，解码经济大省如何擎起聚合世界的责任与担当。 在9月15日上午举行的"活力中国调研行"主题采 ...

Core Viewpoint - The book "The Formation History of the East Asian World" by historian Han Sheng explores the long-standing relationships and cultural exchanges among ancient China, Japan, and the Korean Peninsula, emphasizing the significance of shared cultural elements and their impact on the future of East Asia [4][10]. Group 1: Cultural Foundations - The basic cultural foundations of the East Asian world include Chinese characters, Confucianism, educational systems, legal codes, and Buddhism, which have shaped the region's identity [4][5]. - The use of Chinese characters across countries like China, Korea, Japan, and Vietnam has led to the perception of East Asia as a "Chinese character cultural circle," facilitating communication and cultural exchange [4][5]. - Confucianism has played a foundational role in shaping East Asian culture, influencing moral values and social behavior, which remain evident in contemporary society [4][11]. Group 2: Educational and Legal Systems - The Confucian educational system adopted by the Chinese court has influenced the educational frameworks of East Asian countries for over two millennia, focusing on training officials and practical talents rather than independent scholarship [5][6]. - The legal systems in East Asia have been significantly shaped by Chinese models, with Korea historically operating under the Chinese administrative system, leading to a blend of local and Chinese legal traditions [5][6]. Group 3: Technological and Cultural Exchange - The book highlights the importance of technology in cultural exchanges, noting that ancient Chinese astronomical knowledge was transmitted to Korea and subsequently to Japan, influencing their respective scientific developments [7][8]. - The establishment of specialized institutions for astronomy and calendar studies in East Asian countries reflects the integration of Chinese knowledge and the development of a unique East Asian worldview [8][9]. Group 4: Historical Interactions - The interactions between China, Korea, and Japan are interconnected, with Korea serving as a conduit for cultural and technological transmission from China to Japan, which is crucial for understanding the historical relationships among these nations [10][11]. - The cultural and technological contributions of Korean exiles to Japan after the fall of Baekje in 660 AD played a significant role in shaping Japan's legal and educational systems [9][10]. Group 5: Modern Implications - Despite the apparent divergence of East Asian countries in modern times, the underlying cultural values rooted in ancient traditions continue to influence contemporary social and business practices [11][12]. - The book argues for the importance of cultural diversity and mutual understanding among Asian countries, suggesting that historical cultural exchanges can inform current efforts to foster cooperation and integration [12][13].

Core Viewpoint - The report highlights a significant decline in the company's financial performance for the first half of 2025, with a 42.89% decrease in revenue and a 94.14% drop in net profit, attributed to market demand fluctuations and intensified industry competition [2][16]. Company Overview and Financial Indicators - The company, Hainan Huluwa Pharmaceutical Group Co., Ltd., operates in the pharmaceutical manufacturing sector, focusing on children's health products and traditional Chinese medicine [2][10]. - Key financial metrics for the first half of 2025 include: - Revenue: CNY 507.67 million, down 42.89% from the previous year - Total profit: CNY 8.18 million, down 83.71% - Net profit attributable to shareholders: CNY 2.41 million, down 94.14% [2][16]. - The company reported a total asset value of CNY 2.91 billion at the end of the reporting period, a decrease of 1.72% compared to the previous year [2]. Business Operations and Market Position - The company specializes in the research, production, and sales of pharmaceutical products, particularly focusing on children's medications and health supplements [3][9]. - The product portfolio includes 111 varieties, with 54 specifically designed for children, covering common pediatric diseases [3][9]. - The company has established a modern production base and R&D center in Haikou and Nanning, enhancing its production capabilities [3][4]. Industry Context - The pharmaceutical industry is undergoing significant changes due to policy adjustments and market demand shifts, with a projected decline of 2.8% in the industry overall for 2025 [10][11]. - The government is expanding drug procurement policies, which is reshaping the industry landscape and encouraging innovation [11][12]. - The demand for pediatric medications is expected to grow due to increased health awareness among parents and the expansion of health insurance coverage [12][13]. Research and Development - The company is actively engaged in R&D, focusing on innovative pediatric formulations and expanding its product line to meet market needs [17][18]. - The company has received approvals for several new drug registrations, enhancing its product offerings in various therapeutic areas [18][19]. Marketing and Sales Strategy - The company employs a multi-channel marketing strategy, targeting both traditional and online sales channels to increase market penetration [7][19]. - Efforts are being made to strengthen partnerships with healthcare institutions and retail pharmacies to improve product visibility and accessibility [19].

Market Outlook - The current market is approaching a bull market phase, with 4500 points seen as the true starting point for a bull market, while the current level around 3700 points is considered low and a potential "floor price" [1][3][4] - Systematic risks in the market are currently low, and investors are encouraged to adopt a "do not sell" strategy as the market trends towards a bull phase [4][5] Investment Strategy - Investors should focus on high-certainty stocks within their understanding, emphasizing long-term holding to mitigate market volatility [1][4] - The consumption sector, particularly leading companies in food and beverage, is expected to perform well due to their ability to navigate economic cycles and maintain controllable inventory levels [2][4][12] Sector Insights - The pharmaceutical sector, including innovative drugs and traditional Chinese medicine, is viewed as having significant growth potential driven by an aging population and increasing demand for chronic disease medications [9][11] - The valuation of consumer stocks is considered reasonable, with dividend yields surpassing those of some bank stocks, indicating a favorable entry point for investors [10][12] Cultural Factors - The white liquor sector is perceived as undervalued, with the enduring cultural significance of alcohol consumption suggesting continued demand [13][14] Market Comparisons - The Hong Kong stock market has shown stronger performance than the A-share market over the past year, indicating a synchronized upward trend towards a bull market [14] Technology Sector Perspective - While the technology sector, particularly in AI and robotics, is recognized as a significant growth area, the uncertainty and rapid changes in this field lead to a cautious investment stance, as it conflicts with a long-term holding strategy [15][16]

Group 1 - The core viewpoint of the news highlights the recent performance of Tian Da Pharmaceutical, which saw a stock price increase of 8.57% despite a decline in overall revenue and profit [1][2] - Tian Da Pharmaceutical's cumulative increase over the past month is 2.94%, and 3.55% year-to-date, underperforming the Hang Seng Index by 25.45% [2] - Financial data shows that as of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99%, and a net profit attributable to shareholders of -56.83 million yuan, a decrease of 154.07% [2] Group 2 - Currently, there are no institutional investment ratings for Tian Da Pharmaceutical [3] - The pharmaceutical and biotechnology industry has an average price-to-earnings (P/E) ratio of -2.05 times, with a median of 1.44 times; Tian Da Pharmaceutical's P/E ratio stands at -6.13 times, ranking 136th in the industry [3] - The company focuses on developing traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical sector [4] Group 3 - Tian Da Pharmaceutical is committed to building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards, and creating a new type of traditional Chinese medicine clinic [4] - The company utilizes advanced technologies such as big data and artificial intelligence to enhance its healthcare services and aims to expand its market presence both domestically and internationally [4] - The company has established marketing centers in Shenzhen and Zhuhai, and is gradually setting up branches in the US and Europe to support its international sales and brand development [4] Group 4 - A significant event reminder includes the disclosure of the mid-year report for the fiscal year 2025 on August 28, 2025 [5]

Group 1 - The core viewpoint is that the pharmaceutical market is steadily expanding due to the aging population, leading to a growing consumer base [1] - Both innovative drugs and traditional Chinese medicine are currently undervalued, presenting a good opportunity for investment [1] - The potential in this sector is significant, as the growth space is determined by the consumer base, which could lead to companies in this field achieving high market valuations globally [1]

Core Insights - The current market is experiencing significant activity, and there is speculation about the sustainability of this trend [1] - Lin Yuan, the chairman of Lin Yuan Investment, shared insights on the innovative pharmaceutical and traditional Chinese medicine sectors, emphasizing their potential [1] Innovative Pharmaceuticals - Lin Yuan believes that innovative pharmaceuticals are crucial for the global advancement of China's pharmaceutical industry [1] - The competitive advantage of innovative drugs lies in China's cost-effective engineering and human resources, along with the development of the domestic research environment [1] - It is anticipated that Chinese companies will emerge among the top ten pharmaceutical firms globally [1] Traditional Chinese Medicine - Lin Yuan highlighted that traditional Chinese medicine, particularly proprietary Chinese medicines, is undergoing continuous innovation, especially in application [1] - The total market capitalization of Chinese pharmaceutical companies remains relatively small compared to foreign counterparts, despite the significant demand driven by an aging population [1] - From a valuation perspective, the current market does not appear expensive [1] Investment Timing - Both innovative pharmaceuticals and traditional Chinese medicine are viewed as valuable investment opportunities [1] - The aging population is expected to increase the prevalence of chronic diseases such as cardiovascular and kidney issues, leading to sustained demand for related medications [1] - The expansion of the pharmaceutical market is seen as inevitable due to these demographic trends [1]

Core Viewpoint - The company, Pizhou Huang, expects a year-on-year net profit growth of no less than 25% in the first quarter of 2024, which has attracted significant attention from the industry and investors [1]. Group 1: Financial Performance - In 2023, Pizhou Huang achieved total revenue of 10.035 billion yuan, representing a year-on-year growth of 15.42% [1]. - The net profit attributable to shareholders for 2023 was 2.784 billion yuan, with a year-on-year increase of 12.59% [1]. - 2023 marked the first time Pizhou Huang's annual revenue surpassed the 10 billion yuan threshold [1]. - The expected net profit growth of at least 25% in Q1 2024 is the largest year-on-year increase for the company since 2019 [1]. Group 2: Market Dynamics and Strategy - The growth in 2023 is attributed to increased sales of core products, including the Pizhou Huang series and the Pizhou Huang An Gong Niu Huang Wan [1]. - The company has experienced a strong sales momentum at the beginning of 2024, indicating a favorable market environment [1]. - Industry experts believe that the growing public understanding of traditional Chinese medicine and the support from national policies enhance the market competitiveness of established brands like Pizhou Huang [2]. - Strategic adjustments, including increased investment in research and development and efficient management practices, have contributed to the company's competitive edge [2]. Group 3: Pricing Strategy - A price increase in May 2023, where the retail price of the main product, Pizhou Huang pill, was raised from 590 yuan to 760 yuan per piece, is noted as a factor that may have positively impacted revenue [2]. - The price adjustment was larger than market expectations and is expected to have a significant positive effect on the company's performance [2].

Core Viewpoint - The discussion highlights the role of Traditional Chinese Medicine (TCM) in the prevention and treatment of Chikungunya fever, emphasizing its historical and clinical significance in epidemic control [1][2] Group 1: Disease Overview - Chikungunya fever is an acute infectious disease caused by the Chikungunya virus, primarily transmitted by Aedes mosquitoes, presenting with fever, joint pain, and rash [1] - The virus is sensitive to heat, with 56°C for 30 minutes being sufficient to inactivate it, and various disinfectants and UV light also effective in its elimination [1] Group 2: Historical Context and TCM's Role - Since the founding of New China, TCM has participated in epidemic prevention and treatment, notably during the COVID-19 pandemic, showcasing its unique health perspectives and techniques [2] - TCM emphasizes maintaining the body's own disease resistance and internal balance, which has proven effective in reducing severe cases and mortality rates [2] Group 3: Current Epidemic Insights - The recent Chikungunya outbreak is classified as a "vector-borne epidemic," with the core pathology identified as wind evil attacking the surface and damp heat accumulation [2] - Preventive measures include environmental sanitation, mosquito control, and the use of TCM ingredients like Job's tears and lotus leaves to enhance immunity and alleviate symptoms [2] Group 4: TCM Treatment Principles - TCM treatment principles focus on clearing heat, transforming dampness, and dispelling wind, utilizing both internal and external methods to relieve joint pain and promote recovery [2] - The safety and efficacy of TCM approaches are highlighted, making them suitable for various populations [2]